Cargando…

Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis

Currently several tyrosine kinase inhibitors (TKIs) are approved for treatment of chronic myeloid leukemia (CML). Our goal was to identify the optimal sequential treatment strategy in terms of effectiveness and cost-effectiveness for CML patients within the US health care context. We evaluated 18 tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rochau, Ursula, Kluibenschaedl, Martina, Stenehjem, David, Kuan-Ling, Kuo, Radich, Jerald, Oderda, Gary, Brixner, Diana, Siebert, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689963/ https://www.ncbi.nlm.nih.gov/pubmed/26783469 http://dx.doi.org/10.1155/2015/982395

Ejemplares similares

Application of Decision-Analytic Models in Personalized Medicine for CML Treatment Decisions Made by Payers, Providers, and Patients
por: Saverno, Kim R., et al.
Publicado: (2012)

Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online
por: Jahn, Beate, et al.
Publicado: (2017)

Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making
por: Brixner, Diana I., et al.
Publicado: (2012)

Payer perceptions on the use of economic models in oncology decision making
por: Biskupiak, Joseph, et al.
Publicado: (2021)

Introduction
por: Brixner, Diana I., et al.
Publicado: (2012)

Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia
por: Tadesse, Fisihatsion, et al.
Publicado: (2021)

Payer perceptions of the use of real-world evidence in oncology-based decision making
por: Brixner, Diana, et al.
Publicado: (2021)

Management of chronic myeloid leukemia in 2023 – common ground and common sense
por: Senapati, Jayastu, et al.
Publicado: (2023)

Major progress in understanding progression in chronic myeloid leukemia
por: Radich, Jerry
Publicado: (2015)

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics
por: Willenbacher, Ella, et al.
Publicado: (2016)

Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia
por: Brehme, Marc, et al.
Publicado: (2016)

Analysis of the gap in PCR monitoring availability for patients with chronic myeloid leukemia in 60 low- and middle-income countries
por: Rowley, Seth, et al.
Publicado: (2021)

A population‐based cohort of adult patients with diabetes mellitus in a Western District of Austria: The Diabetes Landeck cohort
por: Haslwanter, Veronika, et al.
Publicado: (2022)

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
por: Cross, Nicholas C. P., et al.
Publicado: (2023)

Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia
por: Vukićević, Đurđa, et al.
Publicado: (2020)

Computational modeling of temporal and sequential dynamics of foraging decisions
por: Jung, Kanghoon, et al.
Publicado: (2014)

From molecular interaction to acute promyelocytic leukemia: Calculating leukemogenesis and remission from endogenous molecular-cellular network
por: Yuan, Ruoshi, et al.
Publicado: (2016)

Solving the Mystery of Myelodysplasia
por: Radich, Jerald
Publicado: (2008)

Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center
por: Stenehjem, David D., et al.
Publicado: (2019)

Bursts and Heavy Tails in Temporal and Sequential Dynamics of Foraging Decisions
por: Jung, Kanghoon, et al.
Publicado: (2014)

“This Drug May Work, But Is It Worth the Cost?” Can Comparative Effectiveness Research Help Tame Rising Health Care Costs?
por: Brixner, Diana I., et al.
Publicado: (2012)

Regulation of myeloid leukemia by the cell fate determinant Musashi
por: Ito, Takahiro, et al.
Publicado: (2010)

Another Philadelphia story*
por: Radich, Jerald P.
Publicado: (2022)

Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia
por: Pokorny, Rebecca, et al.
Publicado: (2022)

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
por: Zhou, Yi, et al.
Publicado: (2016)

Standardizing Quality Assessment of Observational Studies for Decision Making in Health Care
por: Brixner, Diana
Publicado: (2009)

Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia
por: Michelson, Andrew P., et al.
Publicado: (2020)

The Prognostic Significance of IRF8 Transcripts in Adult Patients with Acute Myeloid Leukemia
por: Pogosova-Agadjanyan, Era L., et al.
Publicado: (2013)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
por: Popescu, Bogdan, et al.
Publicado: (2019)

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
por: Stein, Andrew M, et al.
Publicado: (2013)

Rapid detection of myeloid neoplasm fusions using single-molecule long-read sequencing
por: Sala-Torra, Olga, et al.
Publicado: (2023)

Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
por: Flynn, Kathryn E., et al.
Publicado: (2022)

Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria
por: Jahn, Beate, et al.
Publicado: (2019)

Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia
por: Leonard, Sarah M., et al.
Publicado: (2014)

Inhibitory effects of Tomivosertib in acute myeloid leukemia
por: Suarez, Milagros, et al.
Publicado: (2021)

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
por: Mistry, Rohit, et al.
Publicado: (2018)

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
por: Cortes, Jorge E., et al.
Publicado: (2020)

Cell Signaling-Based Classifier Predicts Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia
por: Cesano, Alessandra, et al.
Publicado: (2015)

Unbiased decision-making for acute myeloid leukemia still needed
por: Eisfeld, Ann-Kathrin
Publicado: (2022)

Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia
por: Shelton, Dawne N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ad0euhb7pgcv9jge7memo4tpm1